Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

• Κύριοι συγγραφείς: Zoltán Kaló (Συγγραφέας), Zoltán Vokó (Συγγραφέας), Andrew Östör (Συγγραφέας), Emma Clifton-Brown (Συγγραφέας), Radu Vasilescu (Συγγραφέας), Alysia Battersby (Συγγραφέας), Edward Gibson (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Taylor & Francis Group, 2017-01-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted hea...